2017-03-14,Kura Oncology Reports Fourth Quarter And Full Year 2016 Operational And Financial Results
2017-03-07,Kura Oncology To Report Fourth Quarter And Full Year 2016 Financial Results
2017-03-06,Kura Oncology Reports Updated Clinical Activity Data In Ongoing Phase 2 Trial For Tipifarnib
2017-02-27,Kura Oncology Announces Presentation Of Preliminary Clinical Data For Tipifarnib In HRAS Mutant Squamous Cell Carcinomas Of The Head And Neck At TAT 2017
2017-02-09,Kura Oncology To Participate In Three Upcoming Investor Conferences
2017-01-17,Kura Oncology Doses First Patient In Phase 2 Study Of Tipifarnib In Chronic Myelomonocytic Leukemia
2017-01-04,Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program
2017-01-03,Kura Oncology Appoints Steven Stein, M.D. To Board Of Directors
2016-12-01,Kura Oncology Presents Preclinical Data On KO-947 And Menin-MLL Inhibitor Program At The EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
2016-11-18,Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down
2016-11-15,Kura Oncology To Present Preclinical Data On Pipeline Programs At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
2016-11-07,Kura Oncology Reports Third Quarter 2016 Financial Results
2016-11-04,Kura Oncology Presents Update On Pipeline Programs Targeting RAS-ERK Pathway At European Scientific Oncology Conference
2016-11-01,Kura Oncology To Participate In Two Upcoming Investor Conferences
2016-10-31,Kura Oncology To Report Third Quarter 2016 Financial Results
2016-10-31,Kura Oncology To Participate In The 9th European Scientific Oncology Conference
2016-09-14,Kura Oncology To Participate In The 2016 Aegis Growth Conference
2016-09-02,Kura Oncology To Participate In The 5th Annual Gateway Conference
2016-08-24,7 Stocks Under $10 Making Big Up Moves
2016-08-11,Here's Why Kura Oncology (KURA) Stock Is Soaring Today
2016-08-10,Kura Oncology Reports Second Quarter 2016 Financial Results
2016-08-03,Kura Oncology To Report Second Quarter 2016 Financial Results
2016-06-16,Kura Oncology Doses First Patient In Phase 2 Study Of Tipifarnib In Lower Risk Myelodysplastic Syndromes
2016-06-14,Kura Oncology To Participate In The 2016 JMP Life Sciences Conference
2016-06-03,Kura Oncology To Participate In The Jefferies 2016 Healthcare Conference
2016-05-11,Kura Oncology Reports First Quarter 2016 Financial Results
2016-03-17,Kura Oncology Reports Fourth Quarter And Full Year 2015 Operational And Financial Results
2016-03-11,Kura Oncology To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-04,Kura Oncology To Participate In The Leerink Global Healthcare Conference
2016-01-08,Reverse Mergers Losing Out to Lower-Cost Offerings
2015-12-03,Kura Oncology Announces Data Presentation On Lead Product Candidate Tipifarnib At The Upcoming ASH Meeting
2015-12-01,Kura Oncology To Present At The Oppenheimer 2015 Healthcare Conference
2015-11-30,Kura Oncology To Present At Upcoming Investor Conference
2015-11-30,Kura Oncology Announces First Patient Dosed In An Investigator-Sponsored Phase 2 Trial Of Tipifarnib In Patients With HRAS Mutant Urothelial Cancer
2015-11-11,Kura Oncology To Present At The Jefferies 2015 Global Healthcare Conference
,
,
,
,
